Tetra Bio-Pharma

134 articles about Tetra Bio-Pharma

• Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF

  4/2/2020

  Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma. OTTAWA, April 02, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (“ Tetra ” or the “ Company ”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the launch of a study to determine the levels of cannabinoid metabolites (e.g., 7-CO

• Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A

  3/30/2020

  Tetra Bio-Pharma Inc. , announced today it has filed an amended and restated management’s discussion and analysis for the financial year ended November 30, 2019 (" Restated MD&A "), which is available on SEDAR under the Corporation's profile. The board of directors of the Corporation, based on the recommendation of the audit committee in consultation with the management of the Corpora

• Tetra Biopharma Survey Validates Primary Endpoint of SERENITY© Clinical TrialSurvey respondents are Patients and Physicians from the US and Canada

  3/26/2020

  Tetra Bio-Pharma Inc . (“ Tetra ” or the “ Company ”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced the results of a survey conducted among US and Canadian patients and physicians which validated the primary endpoint of the SERENITY © pivotal trial. The results confirm that the primary endpoint in the SERENITY © clinical trial is accurate About Cancer Cachexia   Fifty to 80% of cancer

• Tetra Bio-Pharma Provides Management Update on COVID-19

  3/23/2020

  Tetra Bio-Pharma Inc . ( today would like to announce that it has ensured that all of its employees work under conditions that comply with federal and provincial public health recommendations. Additionally, following the completion of its $17.8 M financing in February and early March, the Company is in a good position to maintain it

• Tetra Bio-Pharma Engages Alpha Bronze LLC as investor relations and public relations firm

  3/6/2020

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has engaged Alpha Bronze LLC., by its principal, Mr. Pascal Nigen, an investor relations, management consulting and financial communications firm to implement and execute a comprehensive investor relations and communications program.

• Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientificCo-Development will provide pipeline for next generation pharmacology research of Rx drugs to further secure growth for Tetra Bio-Pharma Inc

  2/27/2020

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. 

• Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Type B Meeting with USA FDA

  2/25/2020

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, is pleased to provide additional information on the drug development program for CAUMZ™ following the previously announced Type B meeting with the US Food and Drug Administration.

• Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA

  2/24/2020

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide additional information on the drug development program for QIXLEEF™ following the previously announced Letter of Advice and Type B meeting with the US Food and Drug Administration (FDA).

• 

  Clinical Catch-Up: February 17-21

  2/24/2020

  Mid-February had a solid number of clinical trial announcements. Here’s a look.

• Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs

  2/20/2020

  Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today announced the initiation of its clinical trial for its synthetic cannabinoid therapy (PPP003v) for the treatment of ophthalmic eye pain in the veterinary setting.

• Tetra Bio-Pharma Appoints Sylvain Chrétien as PresidentSeasoned executive brings 31 years of experience leading commercial and business operations of growth-oriented global biopharmaceutical businesses

  2/18/2020

  Tetra Bio Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB: TBPMF) a leader in cannabinoid-derived drug discovery and development, is pleased to announce the appointment of Sylvain Chrétien as President of Tetra Bio-Pharma Inc. Mr. Chrétien will report directly to Guy Chamberland, CEO of Tetra.

• Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints LLC for CAUMZ™ and HCC011

  2/13/2020

  Agreement secures a 2D patented printing technology that will significantly boost production capacity and reduce production costs Further protects CAUMZ™ and HCC011 with four additional manufacturing patents OTTAWA, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Tetra Bio Pharma Inc. (“ Tetra ” or the “ Company ”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced it has signed a definitive manufacturing agreement with Vitiprints LLC, for the

• Tetra Bio-Pharma Provides an Update on Its Veterinary Ophthalmic Clinical Study with PPP003

  1/28/2020

  Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide an update on its veterinary clinical trial to evaluate the safety, tolerability and potential efficacy of its PPP003 ophthalmic drug in the treatment of eye pain in companion animals with indolent corneal ulcers.

• Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs

  1/20/2020

  Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), today provided an update on its commercialization initiatives to bring its OTC Drug Identification Number (DIN) products and natural health products to market in 2020.

• Tetra Bio-Pharma Granted Two OTC Drug Identification Numbers (DIN) by Health CanadaTERPACAN™ receives approval for OTC use in back & muscle pain, and in hemorrhoids; expected to launch both products in Canadian pharmacies by mid-2020

  1/17/2020

  Tetra Bio Pharma Inc. announced that Health Canada has granted two Drug Identification Numbers for the first over-the-counter products to be marketed under its TERPACAN™ banner..

• Tetra Bio-Pharma Receives Favorable Letter of Advice from USA FDA for QIXLEEF

  1/13/2020

  Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced that it has received a favorable Letter of Advice from the US Food and Drug Administration for QIXLEEF.

• Tetra Bio-Pharma Provides Update on U.S. and Canadian Regulatory Activities

  12/19/2019

  Submitted data to U.S. Food and Drug Administration for surrogate endpoint to be used for an Accelerated Approval

• 

  BioSpace Global Roundup, Dec. 19

  12/19/2019

  Companies from across the globe provide updates on their business and product pipelines.

• Tetra Bio-Pharma Signs Definitive Commercialization Agreement for CAUMZ™ in Portugal With Azevedos Indústria Farmacêutica, S.ATetra expands its business relationship with Azevedos as it prepares for commercialization in Europe

  12/16/2019

  Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced the signing of a definitive agreement with Azevedos Indústria Farmacêutica, S.A. (Azevedos) for the marketing and distribution of CAUMZTM (PPP011) in Portugal.  

• Tetra Bio-Pharma Provides Update on its Hepatocellular Carcinoma Drug HCC011

  12/10/2019

  Tetra Bio-Pharma Inc. announced it will be requesting a meeting with the U.S. Food and Drug Administration to discuss the drug development program for its Orphan Drug candidate HCC011, inhaled delta-9-tetrahydrocannabinol, in the treatment of hepatocellular carcinoma.